Ann: Investigators Meeting Completed for BTX 1204 Phase 2 Study, page-10

I have never ever been more excited to be part of a stock on the ASX.

The credentials here are outstanding.

Pfizer pays 5.2 bill for a product that our lovely company is expected to superseed.

There is nothing on the market that has what we have.

"Combined with the pilot efficacy data from its Phase 1b patient study of BTX 1204, Botanix believes that BTX 1204 has the potential to address the multiple pathologies that drive atopic dermatitis including inflammation, bacterial infection, and an immune response that reinforces the skin barrier disfunction and results in increasing pain and itch."

That is just one product for goodness sake.

There is also acne and psoriasis.

BTX1801 again is the sleeper.

Mind blowing.